The Role of Alpha₂-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder

References

• . American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
   Google Scholar
• . Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2008. Vital Health Stat 10. 2009;244:1–81
   Google Scholar
• . Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28(4):265–273
   PubMed Web of Science ®Google Scholar
• . Cuffe SP, Moore CG, McKeown R. ADHD and health services utilization in the national health interview survey. J Atten Disord. 2009;12(4):330–340
   PubMedGoogle Scholar
• . Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921
   PubMed Web of Science ®Google Scholar
• . Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10
   PubMed Web of Science ®Google Scholar
• . Dulcan M; AACAP Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36( suppl 10):85S–121S
   Web of Science ®Google Scholar
• . Hurtig T, Ebeling H, Taanila A, . ADHD and comorbid disorders in relation to family environment and symptom severity. Eur Child Adolesc Psychiatry. 2007;16(6):362–369
   PubMed Web of Science ®Google Scholar
• . Rommelse NN, Altink ME, Fliers EA, . Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. J Abnorm Child Psychol. 2009;37(6):793–804
   PubMed Web of Science ®Google Scholar
• . McBurnett K, Pfiffner LJ. Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders. Postgrad Med. 2009;121(6):158–165
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR, ; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Taylor AA, Pool JL. Clinical pharmacology of antihypertensive therapy. Semin Nephrol. 2005;25(4):215–226
   Google Scholar
• . A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–1086
   PubMed Web of Science ®Google Scholar
• . Pappadopulos E, Macintyre Ii JC, Crismon ML, . Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003;42(2):145–161
   PubMed Web of Science ®Google Scholar
• . Weiss M, Panagiotopoulos C, Giles L, . A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009;19(5):575–582
   PubMed Web of Science ®Google Scholar
• . Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry. 2007;16(2):104–120
   PubMed Web of Science ®Google Scholar
• . De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur Psychiatry. 2006;21(1):21–28
   Google Scholar
• . Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334–347
   PubMed Web of Science ®Google Scholar
• . Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69( suppl 4):9–14
   PubMed Web of Science ®Google Scholar
• . Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886–894
   PubMed Web of Science ®Google Scholar
• . Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila). 2000;39(1):15–25
   PubMed Web of Science ®Google Scholar
• . Connor DF, Findling RL, Kollins SH, . Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms. CNS Drugs. 2010;24(9):755–768
   PubMed Web of Science ®Google Scholar
• . Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1551–1559
   PubMed Web of Science ®Google Scholar
• . Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7–8):579–589
   PubMed Web of Science ®Google Scholar
• . Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1996;53(5):448–455
   PubMed Web of Science ®Google Scholar
• . Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1285–1292
   PubMed Web of Science ®Google Scholar
• . Arnsten AF, Scahill L, Findling RL. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17(4):393–406
   PubMedGoogle Scholar
• . Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002;22(16):7264–7271
   Google Scholar
• . Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57(7–8):608–618
   PubMed Web of Science ®Google Scholar
• . Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 suppl 2):S46–S53
   Google Scholar
• . Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(1):12–13
   PubMed Web of Science ®Google Scholar
• . Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3(5):386–396
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Wang G-J, Fowler JS, . Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121
   PubMed Web of Science ®Google Scholar
• . Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1(1):2
   PubMed Web of Science ®Google Scholar
• . Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs. 2009;23( suppl 1):33–41
   PubMed Web of Science ®Google Scholar
• . Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):376–384
   Google Scholar
• . Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975;92(2):291–306
   Web of Science ®Google Scholar
• . Aston-Jones G, Cohen JD. An integrative theory of locus coeruleusnorepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403–150
   PubMed Web of Science ®Google Scholar
• . Arnsten AFT, Cai JX. Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging. 1993;14(6):597–603
   Google Scholar
• . Wang M, Ramos BP, Paspalas CD, . Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397–410
   PubMed Web of Science ®Google Scholar
• . Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17( suppl 1):i6–i15
   PubMed Web of Science ®Google Scholar
• . Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. α2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13(6):770–776
   PubMed Web of Science ®Google Scholar
• . Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol. 1994;62(2):134–139
   Google Scholar
• . Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport. 2003;14(7):1013–1016
   PubMed Web of Science ®Google Scholar
• . Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol Psychiatry. 2005;57(2):192–195
   Google Scholar
• . Gyires K, Zádori ZS, Török T, Mátyus P. α2-Adrenoceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int. 2009;55(7):447–453
   PubMed Web of Science ®Google Scholar
• . Jasper JR, Lesnick JD, Chang LK, . Ligand efficacy and potency at recombinant α2 adrenergic receptors: agonist-mediated [35S]GTPγS binding. Biochem Pharmacol. 1998;55(7):1035–1043
   PubMed Web of Science ®Google Scholar
• . Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct. 2008;4:12
   PubMed Web of Science ®Google Scholar
• . Bruno KJ, Hess EJ. The α2C-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. Neurobiol Dis. 2006;23(3):679–688
   Google Scholar
• . Cho SC, Kim JW, Kim BN, . Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample. Neurosci Lett. 2008;446(2–3):108–111
   Google Scholar
• . Uhlén S, Wikberg JE. Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991;202(2):235–243
   Google Scholar
• . Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol. 1980;10( suppl 1):71S–80S
   PubMedGoogle Scholar
• . Biederman J, Melmed RD, Patel A, ; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–e84
   PubMed Web of Science ®Google Scholar
• . Jain R, Kollins S, Bailey C, Holloway W, Horacek HJ, Khayrallah M. Developing a sustained release formulation of clonidine for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). Poster presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 7–11, 2008; Scottsdale, AZ
   Google Scholar
• . Hunt RD. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol Bull. 1987;23(1):111–114
   Google Scholar
• . Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry. 1985;24(5):617–629
   PubMedGoogle Scholar
• . Hunt RD, Minderaa RB, Cohen DJ. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull. 1986;22(1):229–236
   PubMedGoogle Scholar
• . Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(1):50–54
   PubMed Web of Science ®Google Scholar
• . Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223–228
   PubMed Web of Science ®Google Scholar
• . Keränen A, Nykänen S, Taskinen J. Pharmacokinetics and side-effects of clonidine. Eur J Clin Pharmacol. 1978;13(2):97–101
   Google Scholar
• . Daviss WB, Patel NC, Robb AS, . Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47(2):189–198
   PubMed Web of Science ®Google Scholar
• . Fujimura A, Ebihara A, Ohashi K, . Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol. 1994;34(3):260–265
   PubMed Web of Science ®Google Scholar
• . Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7(9):558–562
   Google Scholar
• . Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29(4):617–625
   Google Scholar
• . Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253–1262
   PubMed Web of Science ®Google Scholar
• . Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J; SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–165
   PubMed Web of Science ®Google Scholar
• . Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–1055
   PubMed Web of Science ®Google Scholar
• . Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy [letter]. J Child Adolesc Psychopharmacol. 1995;5(4):301–304
   Google Scholar
• . Kollins S, Findling RL, Wigal SB, Brams M, Segal SD, Khayrallah M. Modified-release clonidine for the treatment of children/adolescents with ADHD. Poster presented at: 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 27 –November 1, 2009; Honolulu, HI
   Google Scholar
• . Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501–510
   PubMed Web of Science ®Google Scholar
• . Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–226
   PubMed Web of Science ®Google Scholar
• . Schatzberg AF. New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities. CNS Spectr. 2006;11(12 suppl 15):22–27
   Google Scholar